EchoGo® Heart Failure vs Cleerly LABS
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These tools are adjacent rather than direct competitors, as they leverage different imaging modalities to address distinct cardiac conditions. EchoGo® Heart Failure analyzes echocardiograms for the detection of Heart Failure with preserved Ejection Fraction (HFpEF), whereas Cleerly LABS utilizes coronary CT angiography (CCTA) to characterize atherosclerosis and stenosis for personalized coronary artery disease management.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGou00ae Heart Failure analyzes routine echocardiograms to detect Heart Failure with preserved Ejection Fraction (HFpEF). Cleerly LABS analyzes coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management.
EchoGou00ae Heart Failure provides AI-powered HFpEF detection insights within 20 minutes, delivering automated structured reports. Cleerly LABS offers comprehensive coronary plaque assessment (volume, type), stenosis detection and quantification, 3D visualization of coronary arteries, and personalized heart disease risk assessment, also supporting tracking disease progression over time.
EchoGou00ae Heart Failure offers seamless integration with existing workflows and IT stacks, utilizing a DICOM workflow for report delivery to PACS. It is a cloud-based service that can also use HL7 messaging or an API for increased flexibility. Cleerly LABS integrates with PACS, RIS, and EHR via an on-site Cleerly Proxy for data transfer, and aims to provide customized workflow integration.
EchoGou00ae Heart Failure delivers insights within 20 minutes. The provided information does not specify a turnaround time for Cleerly LABS analysis.
EchoGou00ae Heart Failure is clinically validated with 90% sensitivity and 86% specificity for HFpEF, having undergone rigorous real-world testing. Cleerly LABS is FDA-cleared, and its AI-QCT technology has shown 94.4% agreement with intravascular ultrasound for coronary plaque quantification. The Cleerly ISCHEMIA module, when used with Cleerly LABS, has been validated through multiple clinical trials with invasive FFR as the gold standard, demonstrating higher diagnostic accuracy compared to FFRCT and stress testing in the CREDENCE trial.
More Comparisons
Backers
Who funded each tool's parent company.